Chugai Pharmaceutical Co., Ltd.
4519
Rankning i aktier
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Aktiekurs
$41.60
Marknadsvärde
$68.46B
Förändring (1 dag)
0.94%
Förändring (1 år)
-12.56%
Land
JP
Handel Chugai Pharmaceutical Co., Ltd. (4519)
Kategori
Healthcare
P/B-tal för Chugai Pharmaceutical Co., Ltd. (4519)
P/B-tal per October 2026 TTM: 5.37
Enligt Chugai Pharmaceutical Co., Ltd. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 5.37. I slutet av 2024 hade företaget ett P/B-tal på 6.06.
Historik för P/B-tal för Chugai Pharmaceutical Co., Ltd. från 2003 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 5.37 | -19.88% |
| 2025 | 6.70 | 10.55% |
| 2024 | 6.06 | 12.04% |
| 2023 | 5.41 | 39.01% |
| 2022 | 3.89 | -24.76% |
| 2021 | 5.17 | -43.99% |
| 2020 | 9.23 | 42.83% |
| 2019 | 6.46 | 39.84% |
| 2018 | 4.62 | 1.37% |
| 2017 | 4.56 | 60.55% |
| 2016 | 2.84 | -23.22% |
| 2015 | 3.70 | 36.43% |
| 2014 | 2.71 | 22.38% |
| 2013 | 2.21 | 20.49% |
| 2012 | 1.84 | 21.85% |
| 2011 | 1.51 | -16.66% |
| 2010 | 1.81 | -17.31% |
| 2009 | 2.19 | -7.81% |
| 2008 | 2.37 | 4.04% |
| 2007 | 2.28 | -35.18% |
| 2006 | 3.52 | -8.27% |
| 2005 | 3.84 | 30.96% |
| 2004 | 2.93 | 2.47% |
| 2003 | 2.86 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 31.9092 | 494.46% |
US
|
|
| 7.3138 | 36.25% |
US
|
|
| -84.9599 | -1,682.77% |
US
|
|
| 8.6873 | 61.84% |
US
|
|
| 8.4776 | 57.93% |
CH
|
